# Erenumab For Treatment of Hemicrania Continua

> **NCT04303845** · PHASE2 · TERMINATED · sponsor: **Mayo Clinic** · enrollment: 2 (actual)

## Conditions studied

- Hemicrania Continua

## Interventions

- **DRUG:** Erenumab

## Key facts

- **NCT ID:** NCT04303845
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-08-04
- **Primary completion:** 2022-04-06
- **Final completion:** 2022-04-06
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** difficulty with recruitment
- **Last updated:** 2023-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04303845

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04303845, "Erenumab For Treatment of Hemicrania Continua". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04303845. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*